One-Stop Autologous TAC-T Development Services

Online Inquiry

Background Service Service Packages Workflow Highlights FAQs Contact

The development of autologous cell therapies for solid tumors is often hindered by complex manufacturing hurdles, safety concerns like off-tumor toxicity, and limited therapeutic persistence. Creative Biolabs' One-Stop Autologous TAC-T Development service provides a seamlessly integrated platform to address these challenges head-on. This end-to-end solution encompasses every critical stage from cell isolation to final product characterization and functional validation. Leveraging our proprietary TAC technology platform, we empower partners to accelerate and de-risk their programs by generating potent, durable, and safer T-cell therapies, thereby unlocking their full potential against solid tumors.

Introduction

T Cell Antigen Coupler (TAC)-T cell therapy is a next-generation adoptive cell therapy that redirects T cells to tumor targets by co-opting the complete endogenous T-cell receptor (TCR) complex, rather than relying on synthetic, standalone signaling domains. This fundamental design confers key advantages over conventional CAR-T therapies, most notably a more physiological activation profile that significantly mitigates risks such as severe cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), while potentially enhancing T-cell persistence and efficacy, particularly in solid tumors. Autologous TAC-T Development translates this innovative mechanism into a tailored therapeutic reality, encompassing the entire pipeline from target validation and receptor engineering to clinical-scale manufacturing of patient-specific T-cell products.

Fig.1 Harnessing the T cell antigen coupler for targeted immunotherapy. (Creative Biolabs Original) Fig.1 The T cell antigen coupler (TAC) platform in immunotherapy.

One-Stop Autologous TAC-T Development Services at Creative Biolabs

Creative Biolabs provides an end-to-end infrastructure to transition your therapeutic concept from initial design to clinical-grade production. We specialize in developing TAC-T cells that target challenging antigens, ensuring your project benefits from enhanced tumor infiltration and a reduced inflammatory cytokine profile.

Service Packages

Our integrated development platform delivers a complete, seamless workflow for autologous TAC-T therapies, from foundational cell isolation to final preclinical validation.

Autologous T Cell Isolation & Enrichment Service

This service provides the critical first step in TAC-T manufacturing: the high-purity isolation and enrichment of T lymphocytes from a patient's own starting material, such as peripheral blood. We employ robust, closed-system methodologies like leukapheresis processing followed by positive or negative selection techniques to obtain a defined T cell population. This ensures an optimal foundation for genetic engineering by removing immunosuppressive cells and other contaminants, thereby maximizing the consistency and potential efficacy of the final TAC-T product.

TAC-T Cell Activation, Transduction & Expansion Service

This core service encompasses the genetic reprogramming and manufacturing scale-up of the isolated autologous T cells. We facilitate precise T cell activation, followed by efficient transduction using viral vectors to stably integrate the proprietary TAC construct. Subsequently, the transduced cells undergo controlled, large-scale expansion in optimized culture conditions. This process is designed to generate a therapeutically relevant dose of potent, TAC-engineered T cells while preserving a favorable differentiation state.

TAC-T Product Phenotype & Quality Analysis Service

We offer comprehensive analytical services to characterize the cellular composition and critical quality attributes of the final TAC-T product. This includes detailed immunophenotyping by flow cytometry to confirm TAC expression, assess T cell subsets, and evaluate markers of activation or exhaustion. Furthermore, we perform essential quality control tests, such as viability, potency, and sterility assessments. This profiling ensures the product meets predefined release specifications and provides key data for correlating product characteristics with clinical outcomes.

Autologous TAC-T Functional & Safety Profiling Services

This suite of services is dedicated to rigorously evaluating the in vitro functional potency and safety profile of the manufactured TAC-T cells. We conduct specialized co-culture assays to quantify target-specific cytotoxicity, cytokine secretion, and proliferative capacity in response to antigen-positive cells. Safety assessments include screening for CRS potential and evaluating the risk of on-target/off-tumor or off-target toxicities. These preclinical analyses are crucial for demonstrating therapeutic efficacy and supporting the safety rationale for clinical translation.

Our Service Process

Required Starting Materials: Initially, please supply the specifications of the target antigen, define the requirements for the desired effector cell source, and provide any available binder or scFv sequences for subsequent optimization.

Key Steps:

Workflow of one-stop autologous TAC-T development services at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables: You will receive a detailed Therapeutic Candidate Report, Pharmacokinetic (PK) Data Sheets, and Validated Manufacturing SOPs compatible with decentralized production.

Key Advantages

End-to-End Customized Development: A comprehensive service encompassing custom binder identification, small-scale proof-of-concept validation, and scalable manufacturing for clinical trials.
Advanced Vector Design: Strategic optimization of genetic elements, including codon adaptation and sequence engineering, to ensure maximal receptor expression and functionality in primary human T-cells.
Rigorous Analytical Characterization: Implementation of industry-leading assays to precisely quantify critical parameters such as surface receptor density, cellular metabolic health, and tumor-killing efficacy.

FAQs

Q1: How does TAC technology improve safety compared to conventional CAR-T therapies?

A1: Unlike traditional CAR-T designs that primarily engage a solitary CD3ζ chain, TAC recruits the complete endogenous T-cell receptor (TCR) complex. This engagement mode leads to more physiologically controlled T-cell activation, which significantly lowers systemic release of cytokines such as IL-6. Consequently, the incidence and severity of adverse events like CRS are markedly reduced.

Q2: Can your platform be applied to diverse antigen targets?

A2: Absolutely. Our integrated service platform is built on a modular architecture, enabling flexible and efficient development of TAC-T cells against a wide spectrum of validated tumor-associated antigens. This includes both solid tumor and hematological malignancy targets with the capability to expand to other emerging targets as research advances.

Why Choose Us?

Our One-Stop Autologous TAC-T Development Services integrate pioneering science with proven execution. We offer clinical-stage TAC technology, which uniquely harnesses the endogenous TCR for superior safety and efficacy in solid tumors—an area where conventional CAR-Ts falter. Supported by scalable manufacturing and ongoing trials, we deliver de-risked, high-quality therapies from discovery to clinic.

How to contact us?

Creative Biolabs delivers an integrated, clinically-proven pipeline for Autologous TAC-T Development. Through every stage, from molecular design to automated production, we enable the advancement of more controlled and persistent T-cell therapies designed to overcome solid tumor challenges.

Our specialists are available to support your pioneering programs.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.